Latest news

CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections

Debiopharm Underlines Commitment to Eradicating Antimicrobial Resistance by Sponsoring the 8th Annual World AMR Conference

Debiopharm joins discussions with international health organisations to fight anti-microbial resistance at the 2023 World AMR Congress

One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress

CARB-X Funds The 3rd Round of Debiopharm’s Targeted Antibiotic Program To Combat Resistant N. Gonorrhoeae Infections

Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea